Basophil Activation Test in Double-Sensitized Patients With Hymenoptera Venom Allergy: Additional Benefit of Component-Resolved Diagnostics
The Journal of Allergy and Clinical Immunology: In Practice · 2023
DOI: 10.1016/j.jaip.2023.06.007 ↗Kurz gefasst
Fachartikel in der Zeitschrift The Journal of Allergy and Clinical Immunology: In Practice, 2023. Verfasst von Paul Schmidle und 7 weiteren Autor:innen. Beteiligte Einrichtung: Department of Dermatology and Allergy Biederstein, School of Medicine, Technical University of Munich, Munich, Germany. Hauptthemen laut MEDLINE: Hymenoptera, Arthropod Venoms, Venom Hypersensitivity, Hypersensitivity. Die Arbeit wurde bisher 13-mal zitiert (Crossref) und nennt 35 Literaturangaben.
Abstract (Originalsprache)
BACKGROUND: In Hymenoptera venom allergy serologically double-sensitized patients, it is often difficult to identify the culprit insect for venom immunotherapy (VIT). OBJECTIVES: To evaluate if basophil activation tests (BATs) performed not only with venom extracts but additionally with single component-resolved diagnostics could differentiate between sensitized and allergic individuals and how the test results influenced the physicians' decision regarding VIT. METHODS: BATs were performed with bee and wasp venom extracts and with single components (Api m 1, Api m 10, Ves v 1, and Ves v 5) in 31 serologically double-sensitized patients. RESULTS: In 28 finally included individuals, 9 BATs were positive and 4 negative for both venoms. Fourteen of 28 BATs showed positive results for wasp venom alone. Two of 10 BATs positive for bee venom were only positive to Api m 1 and 1 of 28 BATs only to Api m 10, but not for whole bee venom extract. Five of 23 BATs positive for wasp venom were only positive for Ves v 5 but negative for wasp venom extract and Ves v 1. Finally, VIT with both insect venoms was recommended in 4 of 28 individuals, with wasp venom alone in 21 of 28 patients and with bee venom alone in 1 of 28. In 2 cases no VIT was recommended. CONCLUSIONS: BATs with Ves v 5, followed by Api m 1 and Api m 10, were helpful for the decision for VIT with the clinically relevant insect in 8 of 28 (28.6%) patients. A BAT with components should therefore be additionally carried out in cases with equivocal results.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Dermatology and Allergy Biederstein, School of Medicine, Technical University of Munich, Munich, Germany.
- Center of Allergy and Environment (ZAUM), Technical University of Munich, School of Medicine and Helmholtz Center Munich, German Research Center for Environmental Health, Munich, Germany.
- Department of Dermatology and Venerology, Kepler University Hospital, Linz, Austria.
- Department of Dermatology and Allergy Biederstein, School of Medicine, Technical University of Munich, Munich, Germany. Electronic address: bernadette.eberlein@tum.de.
Zitieren
APA
Schmidle, P., Blank, S., Altrichter, S., Hoetzenecker, W., Brockow, K., Darsow, U., Biedermann, T., & Eberlein, B. (2023). Basophil Activation Test in Double-Sensitized Patients With Hymenoptera Venom Allergy: Additional Benefit of Component-Resolved Diagnostics. The Journal of Allergy and Clinical Immunology: In Practice. https://doi.org/10.1016/j.jaip.2023.06.007
Vancouver
Schmidle P, Blank S, Altrichter S, Hoetzenecker W, Brockow K, Darsow U, et al. Basophil Activation Test in Double-Sensitized Patients With Hymenoptera Venom Allergy: Additional Benefit of Component-Resolved Diagnostics. The Journal of Allergy and Clinical Immunology: In Practice. 2023. doi:10.1016/j.jaip.2023.06.007
BibTeX
@article{Schmidle2023,
author = {Schmidle, Paul and Blank, Simon and Altrichter, Sabine and Hoetzenecker, Wolfram and Brockow, Knut and Darsow, Ulf and Biedermann, Tilo and Eberlein, Bernadette},
title = {Basophil Activation Test in Double-Sensitized Patients With Hymenoptera Venom Allergy: Additional Benefit of Component-Resolved Diagnostics},
journal = {The Journal of Allergy and Clinical Immunology: In Practice},
year = {2023},
doi = {10.1016/j.jaip.2023.06.007}
}
EUVIMED